Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

IGILUC 2019 /
Controversies in the management of prostate cancer

18th - 19th Apr 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 09.05.19
Views: 341

Prof Mach Roach III - University of California, San Francisco, USA

Prof Mach Roach III speaks to ecancer at the 2019 International Gastrointestinal, Liver and Uro-Oncology Conference (IGILUC) in Cairo about the controversy surrounding the use of radiotherapy for patients with prostate cancer.

He discusses whether men with high-risk disease should receive prostate-directed radiotherapy or if the lymphatic system should be targeted too.

Prof Roach III also mentions several recent studies that present immunological, drug, radiation and hormonal data which show that African American men exhibit better outcomes when treated for prostate cancer, despite high mortality rates among this population.

He concludes by describing the use of genomic testing to determine the therapeutic response in patients with prostate cancer.

 

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation